Anti angiogenic drugs

Tyrosine kinase inhibitors have been a quickly growing group of anti-angiogenic drugs that target single or multiple pro-angiogenic receptors such as VEGFR

Clinically used anti-angiogenic drugs mainly include anti-angiogenic monoclonal antibodies (AA-MAs) and anti-angiogenic tyrosine kinase inhibitors (AA-TKIs). Compared with kinase inhibitors, monoclonal antibodies are artificially produced from hybridoma cells and have the advantages of high purity, high sensitivity, strong specificity, and low

by I Saltarella 2024 Cited by 8Hence, several anti-angiogenic drugs that directly target angiogenic cytokines (i.e, monoclonal antibodies, recombinant molecules) or their cognate receptors (

by RI Teleanu 2024 Cited by 453The most common anti-angiogenic drugs applied for cancer treatment. Anti-Angiogenic Drug, Targets, Uses, Side Effects. bevacizumab, VEGF-A

anti-angiogenic therapy for lung cancer and summarizes the clinical applications of anti-angiogenic drugs such as beva-cizumab, ramucirumab, nintedanib, anlotinib, and recombi-nant human endostatin (Fig. 1). Angiogenesis and anti‑angiogenic drugs in tumor tissues Blood vessel growth and formation in normal human tis-

Anti-angiogenic drugs can act as decoy agents, monoclonal antibodies, or tyrosine kinase inhibitors. Bevacizumab was the first anti-angiogenic drug approved for human use, however, its use as monotherapy is inefficient.

by J Welti 2024 Cited by 706anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. angiogenic therapy and development of third-generation anti-angiogenic drug

Anti-angiogenic drugs can act as decoy agents, monoclonal antibodies, or tyrosine kinase inhibitors. Bevacizumab was the first anti-angiogenic drug approved for human use, however, its use as monotherapy is inefficient.

by JM Wu 2024 Cited by 47anti-angiogenic drug medication in cases of refractory anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.